Pseudotumorallesions of bone have been treated with curettage for many years. This surgical technique leaves a bone defect that can be relatively large and needs a long time to heal and grafting is mandatory to avoid to patients a prolonged period ofdisability. To accelerate the process of healing autologous bone graft have since then been a gold standard. However large lesions require large volumes of graft harvesting and subsequent disability from harvesting site. To elude complications from graft harvesting the procedure of using allograft from cadaver donors and bone substitutes has been advocated. Neither allograft nor synthetic bone substitutes (ceramics) have however the potentiality of osteoconduction, osteinduction and ostegenesis of autologous bone which is needed to obtain healing, and consequently healing time was protracted.
The original aim of our procedure was to produce an enriched bone graft that could mimic the healing properties of the autologous bone graft, in order to avoid the complications of graft harvesting from iliac crest and to obtain with a relatively simple procedure a safe and effective graft theoretically without amount limits.
MATERIALS AND METHODS
Checking the literature we can separate four major varieties of cell-based tissue engineering: 1) the stimulation of connective tissue progenitors in the site of the defect; 2) transplantation of autologous connective progenitors to improve the present cell number (1); 3) transplantation of cultured cells or genetically modified cells (2); 4) transplantation of a fully formed tissue (3) . The first method is to stimulate tissue formation by stimulating the activation, migration, proliferation, and/or differentiation of local connective tissue progenitors. Implant of an allograft or a synthetic scaffold, but also demineralized bone matrix or bone morphogenetic proteins can simply explain this strategy. Biophysical stimulation, such as mechanical loading, electromagnetic stimulation or ultrasound can also be taken into account when dealing with this approach. In the second way the addition of osteoblastic cells at the defect is thought to stimulate bone formation. Autologous bone graft is one of the most prevalent and relatively effective example ofcell transplantation. Also injection of only stem cells of bone marrow fraction have been used to obtain a similar results and the success rate is dependent on the number of stem cells [1] . In the third method the cells are harvested and expanded in culture medium and then transplanted alone, with growth factors associated or seeded on a scaffold (2). This method seems very promising and some data on animal and clinical studies have been reported. On the other side culture expansion adds substantial cost and some risks, such as contamination with bacteria or viruses or depletion of the proliferative capacity of the stem cells which seem to arrive at a plateau also in vitro. Along with in vitro expansion stem cells can also be genetically modified to express different factors (BMPs the most popular). The complexity of the procedure will probably confine its clinical use in the setting of inherited genetic defects (e.g., Osteogenesis imperfecta). The fourth but by sure not the least method to obtain bone regeneration is the creation of a fully organized and vital tissue by ex vivo method followed by transplantation and integration (4) .
To treat patients with pseudotumoral lesions we decided to use autologous stem cells in addition to homologous bone grafts (cancellous bone chips) and autologous growth factors (platelet rich plasma). We avoided expanded stem cells because oncogenic risk was yet not elucidated at the time we began this surgery and costs were too high to be justified. The rational was to have the best affordable scaffold in our opinion, i.e. allograft bone, to provide osteoconduction; concentrated autologous bone marrow to raise the number of mesenchymal stem cells and to provide osteogenesis and platelet rich plasma to increase local concentration of growth factors.
Bone Marrow preparation
Sepax Procedure: Bone marrow was aspirated from the posterior iliac crests with the patient under general or local (spinal or epidural) anaesthesia. Two small cuts (not requiring stitches) were made bilaterally in the skin over the pelvic bone. After deep insertion of a bevelled tip needle 6 to 8 em long and 1.5mm in internal diameter into spongy bone, the marrow was aspirated into a IOml plastic syringe. The marrow was aspirated through multiple punctures, in small fractions 2 to 5 rnls, to reduce the degree of dilution by peripheral blood, moving the needle toward the surface through the same insertion site, beginning successive aspiration always turning the needle 45°after each aspiration. Using the same skin opening, several perforations were made into the iliac crest. All aspirates were pooled in a 300 mL Teruflex" Transfer Bag (TERUMO®) containing 50 mL of ACD (Anticoagulant Citrate Dextrose) solution. Bone marrow was processed in the laboratory of the BMT Unit, Hematology Division, of Careggi Hospital, to increase its stem cell content. It was reduced in volume to remove the red blood cells and the plasma, and retain only the mononucleated cell (MNCs) fraction containing mesenchymal and hematopoietic stem cells. A manual or an automated procedure performed the concentration, after an initial evaluation of the volume and cellular content of the harvest, and its sterility test to evaluate eventual microbial contamination. Manual procedure: Aspirates were filtered to remove cellular aggregates and fat and then concentrated through centrifugation in a cell separator (ALC 4237R refrigerated centrifuge) at 2000 rpm for 10 minutes. The Iyrnphoidmononuclear layer (buffy coat) was then obtained with a final volume varying according to the volume of the orthopaedic lesion and collected in a 50ml plastic tube. A small sample (lml) was draft to check again sterility status and another one (500IlI, resuspended in sterile HBSS (Hank's Balanced Salts Solution, without Ca-Mg, Eurof'lone") to a final volume of 5 mL to count the recovered cells and rule out CFU-F test. The suspension was stored at 4°C until the injection. Automated procedure: the automated procedure was performed using the SEPAX system (BIOSAFE SA, Switzerland, an ISO 900llEN 46001 certified company), a centrifugation device for automated processing of blood components in a closed and sterile environment. The blood components are collected in standardized bags, ready for further processing (e.g. cryopreservation, in vitro expansion or transfusion into a patient). The SEPAX system consists of I) the machine, the SEPAX device which executes the cell processing process; 2) the separation kit, a configuration with a processing chamber (in the form of a syringe pump to allow both the centrifugation of the blood sample and the transfer of the sample from the reservoir bag to the various collection bags) stopcock manifold, tubes and collection bags; it is sterile, pre-connected and for single-use; its spike is compatible with all membrane ports with, a diameter of 4-6mm; 3) protocol, computer programs managing the machine and the interface between user and machine for different applications. The buffy coat fraction was isolated using the SEPAX protocol termed "BONE MARROW", designed for routine processing of umbilical cord blood, that allows a high red blood cell depletion with a volume reduction in 25 to 30 minutes to a predetermined fixed volume between 20 and 50 mL: the procedure starts by filling the separation chamber as the blood from the source bag is aspirated into the chamber by a downward movement of the piston; this filling phase ends when the optical sensor detects that the supplying tube is empty or when the chamber is full. At the beginning of the sedimentation period the chamber starts rotating along its axis; the centrifugation lasts for a few minutes and results in an optimal separation of the blood components. Finally in the extraction and collection phase, the separated blood components are distributed into the respective collection bags; the procedure is complete when the piston has reached the top of the chamber and the product in the "product bag" (150 mL Teruflex" Transfer Bag, TERUMO®) is ready for further use. A little sample (500IlI) of the product was taken to evaluate cellular loss during the separation procedure: it is suspended in sterile HBSS (Hank's Balanced Salts Solution, without Ca-Mg, Eurof.lone") to a final volume of 5 mL to count the recovered cells and rule out CFU-F test. If necessary the suspension was stored at 4°C until the injection. We never needed to store the suspension longer than 2 hours.
RegenKit Extracell Procedure: in the last years we have used a simplified and less costly procedure with the RegenKit Extracell, class lIb medical device, (RegenLab SA, En Budron B2, 1052 Le Mont, Switzerland) which comes in a sterile package and affords treatment of a single case. The kit is composed by a trocar for bone marrow aspiration, 4 vacuum tubes for isolation of cells and platelets, calcium gluconate for activation if needed. We perform bone marrow collection with the technique already described, but we collect 40 ml of bone marrow. The tubes are then centrifugated inside metallic cylinders to preserve sterility. Centrifugation is performed for 2'at 4000 rpm and then 8'at 3500 rpm. The tubes are then collected in a sterile way from the cylinders and the buffy coat is aspirated. The final product is ready for infiltration or for mixing whit scaffold. We do not usually add calcium gluconate when we mix the buffy coat with bone allograft or demineralized bone matrix powder.
Platelet concentrates preparation
Platelet concentrates were collected from each patient the day before the operation at the Immunohaematological and Transfusional Medicine Service of Careggi Hospital. Two collection techniques have been performed. Some patients underwent an autologous plateletpheresis with the Haemonetics MCS+ collection system; a target dose of 100 x 10 9 platelets was chosen to achieve an adequate harvest. In some other cases, an autologous blood donation of 350 mL was performed; the whole blood was then fractionated into the components (red blood cells, platelets concentrates, plasma and leukocyte buffy-coat) in a quadruple bag system. In both cases, the platelet concentrates were then delivered to the BMT Unit laboratory and centrifuged at 2300 rpm to reduce the volume; the plasma rich in the factors of the coagulation cascade was collected in a separate bag.
Bone Graft
The graft used for filling the defects and form the osteconductive material which should be the scaffold for BMSC has always been homologous cancellous bone graft provided from our Regional Bone Bank (also approved National Bone Bank). The bone graft provided from our bone bank has been alternatively fresh frozen bone or lyophilized cancellous bone chip, both harvested from cadaver donors. At the harvest time the available donor is subject to serologic examination for potentially transmissible disease, while bone is harvested as a whole segment under sterile conditions and tested immediately for bacterial contamination. After microbiological testing bone segment is submersed in an antibiotic solution for 30' and successively packed in three sterile plastic bags and 1 tissue-notissue sheet. The outer side, not sterile, is immediately marked for identification of the segment and then two x-rays are taken to obtain reproducible measurements. The bone was immediately stored at -20°and after 24 hours stored at -80°. After the validation of all microbiological and serological tests the bone is judged safe and sound for implantation. Based upon the surgeon preference the bone graft is provided as a fresh frozen bone segment of a sterile package with fixed amount of lyophilized bone chips. In the first case in the operating room on a separate table the assistant unpack the bone changing gloves for every sterile package with the help of the surgical nurse. The bare bone is then tested again with two swabs for microbiological assessment and submersed in a saline solution added with antibiotics. Preparation of cancellous bone chips of intermediate dimension is done using motorized bone milling instruments (Zimmer). Bone chips are repeatedly washed with pulsed saline solution to eliminate the fat marrow still present. In the last years we began to use lyophilized bone graft instead of fresh frozen bone. The bone collected by our Bone Bank where sent to TISSUELAB S.p.a, which processes human musculoskeletal tissue in conformity to GMP rules to obtain a pharmaceutical level freeze-dried bone graft. Among various available products we have used freeze-dried cancellous or cortico-cancellous granules. The sterile package was open in the operatory room and the freeze-dried chips were re-hydrated at least 30' before handling. At this time we wait till curettage of the lesion is complete to begin mixing the components.
Surgery
Percutaneous infiltration: the patient is positioned in the operatory room and under fluoroscopic control the lesion in centred and two trocar needles (8 gauge) inserted in the cavity. With a well-described technique (4) the lesion is washed with sterile saline solution to eliminate fibrous walls; a needle is then removed and concentrated bone marrow is inserted in the cavity.
Open surgery: In all cases we used manual and motorized curettage instruments (curettes and burrs). In the aneurismal bone cysts and in the giant cell tumour cases we used also local adjuvants like phenol or cryotherapy. When epiphyseal cartilage was exposed we did not use adjuvants.
Preparation ofthe clot
The clot was prepared directly in the surgery room immediately before the implantation. In a sterile glass Becker bone marrow buffy-coat was added to the scaffold and to platelet concentrate; the container was gently rotated until complete clotting was reached (from 4 to 8 min); the serum formed during coagulation process was aspirated and transferred to hemoculture containers for sterility check.
Implant
The concentrated clot was put inside the lesion: The material was packed in the defect and at the end of the procedure an intraoperative X-ray was taken to assess an adequate filling. The patient was immobilized with a cast for lesions in the lower limbs and with splints for the upper limbs. The immobilization was usually removed at the first follow up visit.
Follow up
Patients underwent serial follow up visits, at one month from operation, at 3, 6 months and a year from surgery. Then follow up was continued every 6 months for two years in the pseudotumoral lesion and for five years in the benign tumours. Clinical examination with recording of function, pain and range of motion was evaluated and registered. Every time radiographic examination was performed till healing of the lesion. Follow up visits were performed alternating plain X-rays with Magnetic resonance or computed tomography imaging. A successful clinical result was considered the resume of a normal function, with no pain and impairment from the operated limb. Weatherrelated pain was not considered to alter the result negatively. Radiological healing was assessed when the graft was integrated with disappearing of the limits of the previous cavity and visualization of bone trabeculae inside the void.
RESULTS
From 2000 till June 2010 we retrospectively reviewed 143 patients, which were treated with an enriched graft. The patients were selected by initial diagnosis and for this series 76 cases of pseudotumoral lesions were recorded. The 76 procedures in 63 patients were performed for the following pathologies: 35 aneurismal bone cysts, 13 unicameral bone cysts, 7 aneurismal bone cysts associated to fibrous dysplasia, 5 cases stage I giant cell tumour, 3 cases of benign fibrous histiocytomas, 3 chondroblastomas.
Seventeen patients in these series where treated with percutaneous infiltration of autologous concentrated bone marrow. After 2005 we began to use demineralized bone matrix in addiction to concentrated autologous bone marrow, like described by Docquier and Delloye (5) . Among the seventeen patients treated with percutaneous infiltration 8 patients were considered clinically and radiographically healed with obliteration of the cyst. Five of these patients healed with a single percutaneous infiltration of concentrated autologous bone marrow, while other 3 patients needed a second infiltration to heal. Nine patients did not heal with percutaneous infiltrations and were considered a failure. They were treated with conventional open surgical technique and subsequently healed. Two patients of this series had an aneurysmal cyst associated to fibrous dysplasia.
Forty-six patients were operated with open surgery, and 41 of these patients healed after the treatment, while 5 patients did not heal and required further surgery. We had recurrence of 3 cases of aneurismal bone cyst, I case of giant cell tumour and a patient with a fibrous dysplasia. The 3 cases of aneurismal bone cyst where treated with open surgery, cryotherapy and conventional allograft bone chips; the giant cell tumour was treated with a repeated curettage with local adjuvants (phenol) and filling of the cavity with cement. All healed successfully after second surgery. The patient with the fibrous dysplasia had a pathological fracture and needed open reduction and internal fixation (ORIF). All 5 patients have been considered failures for the statistical purpose of the study, even if they healed after repeated treatment.
The medium time of healing was 6 months for the percutaneous group, both by clinical and radiographic criteria. The open surgery group showed clinical healing at a medium follow up of 3 months, while the radiographic appearance was of healing at 3 months in only 4 of the patients (10% of the healed group) and radiographic healing was sure at 6 months in the remaining 37 cases. While it was evident that healing needed a longer time in percutaneous treatment, clinical results at three months were already good in the totality of the patients arrived at recovery, while the patients which were not healed at that follow up did not recover afterwards and were considered a failure at the latest follow up available. Six months was the median time to obtain a radiographic aspect of healed bone, which for us was a very good result using enriched allograft bone. It was not possible to discover a correlation between size ofthe lesion and its healing, for the variables to consider (age of the patient, site ofthe lesion, diaphyseal or metaphyseal) where too sparse to obtain statistical significance. In the Sepax group the medium volume of harvest was 196.37 ml, while after concentration the medium volume obtained was 29.12 ml. With the RegenLab technique we harvested fixed volumes of 40 or 20 mls for a final volume of 16 or 8 mls. During utilization of Sepax technique we performed an internal control study to validate results of the technique: the total number of reinfused cells was 3.27 x 10 9 on average (1.37-6.35), with a concentration of CD34/45 positive cells of 3.02 % and a total number of fibroblasts colony forming unit (CFU-F) of 32.76 x 10 6 on average (11-145). It was not possible to recover a correlation between number of CFU-F and final result. Platelet utilization proved to be very effective with a percentage of93% ofsuccess in patients where platelet rich plasma was added to final preparation ofthe graft. Addition of Demineralized Bone Matrix (DBM) to the preparation did not obtain significant improvement in terms of healing. We used DBM in 12 patients and observed healing in 8 out of 12 patients, the same results obtained in the patients which were not treated with DBM.
DISCUSSION
Bone healing process has been extensively studied, yet not thoroughly comprehended. Recent studies about stem cells and growth factors as way of implementation of bone grafts introduced new perspectives, new expectations and moreover new doubts of efficacy and safety. A very small number of studies, to our knowledge, have been published about the clinical use of growth factors and stem cell with bone graft in clinical setting. Even with the limitation of the relatively small number of patients our retrospective study proved that a composite graft is easy to obtain and manipulate in clinical setting; it offers good results, presents no disadvantages in respect to safety issues or additional contraindications. When investigating the different method of harvesting autologous bone marrow we found that 39 out of49 patients treated with SEPAX method healed, with a percentage of success of 80%; in the RegenLab method 10 out 14 patients healed, with a slightly lower percentage of 71,4%. However the difference was not statistically significant, and we decided to continue employment of RegenKit Extracell for it is surgeon operated, cheaper and faster. We also performed an internal clinical study to validate the technique of RegenLab Extracell method and found reproducible values between harvested bone marrow, with the natural dispersion of biologic data.
In our opinion the routine use of tissue engineering is not advisable in all clinical settings, but has proven to be effective to treat large bone defect in order to expedite the healing time and reduce functional impairment for the patients. In our opinion cavitary lesions created by curettage of a pseudotumour are ideal settings for using enriched graft, because they present a biological chamber inside which "healing processes can be enhanced by the presence of growth factors. Moreover vascularity is usually not a problem in this category of disorders and mesenchymal elements afford to survive and replicate in a local environment, which helps differentiation of an osteogenic lineage. In these disorders there is extreme variability for aggressiveness, volume, site of the lesions, age ofthe patients and these data prevented us to perform a prospective study that can be validated with control cases. Our data are retrieved from previous personal experience and data from literature.
Last but not least the choice of using MSC from the bone marrow has been proved to be an orthotopic application and also the new laws recently approved by Italian Government about this topic allow its use. Using MSCs concentrated from adipose tissue or expanded cells is still very difficult and in our opinion can be considered only for study reasons. The difficulty to obtain expanded MSCs and their cost restrain their use for pathologies that can be effectively treated with simpler methods.
